New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
10:00 EDTHK, FRX, AWI, WETF, ORLY, PFE, MRK, FRC, CVX, AGN, ZNGA, OPEN, GILD, DRE, CBT, OIS, CRM, NLSN, GPS, DVN, ANGIOn the Fly: Analyst Upgrade Summary
Allergan (AGN) upgraded to Buy from Neutral at Citigroup... Angie's List (ANGI) upgraded to Outperform from Market Perform at Barrington... Cabot (CBT) upgraded to Buy from Neutral at SunTrust... Chevron (CVX) upgraded to Strong Buy from Outperform at Raymond James... Devon Energy (DVN) upgraded to Outperform from Neutral at Credit Suisse... Duke Realty (DRE) upgraded to Outperform from Sector Perform at RBC Capital... First Republic (FRC) upgraded to Outperform from Market Perform at Keefe Bruyette,,, Gap (GPS) upgraded to Buy from Neutral at UBS... Gilead (GILD) upgraded to Outperform from Neutral at RW Baird... Merck (MRK) upgraded to Buy from Neutral at SunTrust... Nielsen (NLSN) upgraded to Buy from Hold at Pivotal Research... OpenTable (OPEN) upgraded to Neutral from Sell at Citigroup... Pfizer (PFE) upgraded to Buy from Hold at Jefferies... Salesforce.com (CRM) upgraded to Buy from Neutral at Roth Capital... Zynga (ZNGA) upgraded to Buy from Neutral at UBS... O'Reilly Automotive (ORLY) upgraded to Buy from Neutral at Northcoast... Oil States (OIS) upgraded to Buy from Accumulate at Tudor Pickering... Armstrong World (AWI) upgraded to Buy from Hold at Gabelli... Halcon Resources (HK) upgraded to Neutral from Reduce at Global Hunter... Wisdom Tree (WETF) upgraded to Buy from Neutral at BofA/Merrill... Forest Labs (FRX) upgraded to Overweight from Neutral at JPMorgan.
News For AGN;ANGI;CBT;CVX;DVN;DRE;FRC;GPS;GILD;MRK;NLSN;OPEN;PFE;CRM;ZNGA;ORLY;OIS;AWI;HK;WETF;FRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
July 26, 2015
12:17 EDTAGNTeva to cancel Mylan bid, plans offer for Allergan generics unit, Bloomberg says
Subscribe for More Information
July 24, 2015
18:36 EDTAGNAllergan considers split into two businesses, Bloomberg reports
Subscribe for More Information
18:25 EDTAGNAllergan considering breakup of company, Bloomberg reports
Allergan is reportedly working with advisors and leaning towards a sale or spinoff of generics, Bloomberg added.
06:27 EDTGILDGilead price target raised to $131 from $120 at Piper Jaffray
Subscribe for More Information
July 23, 2015
12:45 EDTGILDGilead July weekly volatility elevated into Q2 and outlook
Subscribe for More Information
11:04 EDTMRKMerck announces EMA acceptance of MAA for grazoprevir/elbasvir
Subscribe for More Information
July 22, 2015
15:41 EDTANGIAngie's List price target lowered to $5.50 from $8 at Piper Jaffray
Subscribe for More Information
08:32 EDTPFEPfizer expands lease agreement with MIT subsidiary
Subscribe for More Information
07:11 EDTANGIAngie's List reports Q2 EPS (14c), consensus (17c)
Subscribe for More Information
07:04 EDTMRKMerck's Keytruda approved by EU for treatment of advanced melanoma in adults
Merck announced that the European Commission has approved KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of advanced melanoma in adults. The European Commission approval of pembrolizumab is based on data from three clinical studies conducted in more than 1,500 first-line and previously-treated patients with advanced melanoma. Pembrolizumab received European Commission regulatory approval based on Phase 3 data which showed it is the first and only anti-PD-1 therapy to provide a statistically superior survival benefit as a monotherapy compared to ipilimumab, the current standard of care for advanced melanoma. Today’s approval allows marketing of pembrolizumab in all 28 EU member states at the approved dose of 2 mg/kg every three weeks. The European Commission’s approval is based on data from three studies -- KEYNOTE-001, KEYNOTE-002 and KEYNOTE-006. These studies evaluated the efficacy and safety of pembrolizumab in advanced melanoma patients – across treatment lines, prognostic factors, tumor characteristics, and BRAF mutational status – and established 2 mg/kg every three weeks as the approved dose.
06:39 EDTCVXEuro, U.S. oil and gas groups to find tough competition in Iran, WSJ says
European and U.S. oil and gas firms drawn to Iran as sanctions lessen can expect not only opportunities, but also Iranian companies offering tough competition or joint ventures, the Wall Street Journal reports. Though no Iran-based companies have the clout of firms such as Exxon Mobil (XOM) or Schlumberger (SLB), companies that can take on engineering tasks are emerging and growing in Iran, the report says. If the Iran nuclear agreement comes into effect and sanctions are lifted against Iran sometime soon, those Iranian companies will be well positioned to compete for tens of billions of dollars worth of service contracts, the report adds. Other publicly traded companies in the space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Royal Dutch Shell (RDS.A) and Total (TOT). Reference Link
06:29 EDTDVNDevon Energy coverage assumed with an Outperform at Credit Suisse
Target $83.
06:05 EDTMRKMerck, Ablynx expand immuno-oncology collaboration
Subscribe for More Information
05:24 EDTCRMStocks with implied volatility movement; CHK CRM
Subscribe for More Information
July 21, 2015
15:11 EDTCRMEarnings Watch: Microsoft up 5% since announcing Nokia writedown
Subscribe for More Information
14:12 EDTGILDGilead reports study of E/C/F/TAF met primary endpoint
Gilead Sciences announced detailed 48-week data from an open-label Phase 3 study evaluating its investigational once-daily single tablet regimen of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg, or E/C/F/TAF, among 1,436 virologically suppressed adult patients switching from tenofovir disoproxil fumarate-containing regimens. The study met its primary endpoint by demonstrating non-inferiority of E/C/F/TAF to the TDF-based regimens at Week 48. The study also demonstrated statistical superiority among patients with HIV-1 RNA levels less than 50 copies/mL at Week 48 and statistically significant improvements in bone and renal laboratory parameters. These data were presented in an oral session at the 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention in Vancouver, Canada. Among the 1,436 patients who were randomized in the study, virologic success rates at Week 48 were higher in patients taking E/C/F/TAF, 97% versus 93% for all TDF-based regimens; difference in percentages: 4.1%, 95% CI: 1.6% to 6.7%. The rates of virologic failure were similar between the two arms, with E/C/F/TAF, 1.0% and TDF-based regimen, 1.3%. General safety was similar between the two arms through 48 weeks of treatment, with similar percentages of patients in each group having any adverse events. Adverse events leading to treatment discontinuation were more common among patients treated with a TDF-based regimen.
09:56 EDTCRMSalesforce rallies amid renewed speculation of Microsoft deal
Subscribe for More Information
09:55 EDTCRMSalesforce calls active
Subscribe for More Information
08:04 EDTPFEPfizer launches Caltrate Bone & Joint Health supplement
Pfizer Consumer Healthcare announced the launch of Caltrate Bone & Joint Health, a 3-in-1, triple action product that delivers UC-II, an exclusive form of collagen, to support healthy cartilage and promote joint flexibility, calcium and vitamin D3, to nourish strong and healthy bones, and vitamin C and minerals to support collagen production for healthy bones and skin.
06:07 EDTGPSONUG: Yahoo hires VP of global network from Symantec
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use